Description
Camizestrant is an oral selective estrogen receptor degrader (SERD) used in the treatment of estrogen receptor-positive breast cancer. It works by binding to estrogen receptors and promoting their degradation, thereby blocking estrogen signaling pathways that drive tumor growth. This medication is typically used in patients with advanced or metastatic hormone receptor-positive breast cancer.
Mechanism of Action
Binds to estrogen receptors with high affinity and promotes receptor degradation, leading to reduced estrogen receptor levels and inhibition of estrogen-dependent gene transcription and cell proliferation.
Side Effects
Fatigue
Nausea
Decreased appetite
Diarrhea
Hot flashes
Headache
Vomiting
Constipation
And potential liver enzyme elevation.
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT06188520
Phase 1
Recruiting
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
United States, Australia, South Korea, Spain, United Kingdom
NCT04644068
Phase 1
Active, not recruiting
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
United States, Australia, Canada, China, Czechia, Hungary, Italy, Japan, Poland,